Conference abstract · 31 Jul 2017
Conference abstractPublished 14 Sep 2015
Clostridium difficile- An evolving pathogen
TranScrip Partners, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The remarkable emergence of Clostridium difficile in the past decade has led to a plethora of approaches to containing and treating the organism as infection recurrence, changing epidemiology, healthcare costs increase and the recent impact of recurrent infections on the US healthcare payment system has caused concern. Until 2012 there had not been any new advances in the management of this pathogen for 30 years with metronidazole and oral vancomycin being the only therapies available. Fidaxomicin was approved in both US and Europe for the treatment of C difficile infection (CDI). However for various reasons, most financial, this new agent has not been widely adopted even in recurrent cases of CDI. So there is still a need for new methods of ensuring CDI is a less worrying pathogen. Since 2008 there have been several different approaches adopted to manage CDI these include new antibiotics such as surotomycin, cadazolid and SMT 19969, anti-toxin agents, vaccines and biological agents such as non-toxigenic C difficile or faecal transplantation (FMT). In addition some nations have instituted major reviews of the infection control methods and achieved significant reductions in the incidence of CDI in hospitals. However it has been reported that up to 40% of CDI cases now originate in the community setting as opposed to the nosocomial environment. This review will discuss the changing epidemiology, the agents in development and the effect financial controls may have on this disease.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 14 Sep 2015
SMT 19969: A selective agent for Clostridium difficile infection
Article · 29 Apr 2024
The Pharmacological Management Approaches to Clostridium Difficile Infection
Conference abstract · 26 Jun 2021
The Effect of next generation probiotics (NGPs) on Clostridium difficile Sporulation
Mini review · 18 Jun 2020
Clinical Approach of Clostridium Difficile-Associated Diarrhea (CDAD) Treatment by Oral Vancomycin of Isolated Stool Samples of Contaminated Drinking Water in Basrah, Iraq
More from this journal
The newest in Journal of Drug Metabolism & Toxicology.
Short communication · 30 Dec 2025
Liver Drug Metabolism Mechanisms Challenges and Future Perspectives
Opinion · 30 Dec 2025
Hepatic metabolism forms the foundation of drug disposition in the human body
Opinion · 30 Dec 2025
Biomarkers of Toxicity for Monitoring Adverse Drug Reactions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Drug Metabolism & Toxicology
- SubjectDiabetes & Endocrinology
- SubjectPharmaceutical Sciences
- SubjectToxicology
- BylineArticles whose byline prints “Glenn S Tillotson”

